Home › Regeneron Pharms Downgraded by Brean Murray
 

Keywords :   


Regeneron Pharms Downgraded by Brean Murray

2013-01-18 05:36:43| Biotech - Topix.net

A number of other firms have also recently commented on REGN. Analysts at Robert W. Baird raised their price target on shares of Regeneron Pharms from $176.00 to $205.00 in a research note to investors on Tuesday.

Tags: murray downgraded brean regeneron

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.11
17.11
17.11
17.11jindaiji mountain works
17.1121SW 10000PG
17.11Roland Rubix24
17.11 NEO SALA 27.0cm
17.11TXT FC
More »